Skip to Main Content

Paper Details

Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.
JNCI Cancer Spectr
2
2022
A, BC, BCSM, ER, ER-positive, ER-positive BC, Estrogen, Estrogen Receptor, Estrogen Receptor-Positive, Estrogen Receptor-Positive Breast Cancer, HER2, Ki67, MBD, PR, Patients, Tamoxifen, breast cancer, estrogen, estrogen receptor, luminal A-like, luminal B-like, patients, progesterone, progesterone receptor, tamoxifen, tumor, tumors, women
Author NameAffiliation
Sarah J NyanteUniversity of North Carolina at Chapel Hill
Ruth M PfeifferNational Cancer Institute, National Institutes of Health
Ruth M PfeifferNational Cancer Institute, National Institutes of Health
Clara BodelonNational Cancer Institute, National Institutes of Health
Melissa A TroesterUniversity of North Carolina at Chapel Hill
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest
Mark E ShermanMayo Clinic
Mark E ShermanMayo Clinic
  • 1 - 8

Datasets

Release 1.2